Matching articles for "OxyNeo"
Opioids for Pain
The Medical Letter on Drugs and Therapeutics • December 12, 2022; (Issue 1665)
A new CDC guideline for prescribing opioids for pain
recently became available. Nonopioid drugs for pain
were reviewed in a previous...
A new CDC guideline for prescribing opioids for pain
recently became available. Nonopioid drugs for pain
were reviewed in a previous issue.
Comparison Table: Some Oral/Transdermal Opioid Analgesics (online only)
The Medical Letter on Drugs and Therapeutics • December 12, 2022; (Issue 1665)
...
View the Comparison Table: Some Oral/Transdermal Opioid Analgesics
Opioids for Pain
The Medical Letter on Drugs and Therapeutics • April 9, 2018; (Issue 1544)
Use of nonopioid drugs for pain was reviewed in a
previous issue. For many types of moderate to severe acute pain, acetaminophen and/or an NSAID may be as effective as an opioid. Immediate-release formulations...
Use of nonopioid drugs for pain was reviewed in a
previous issue. For many types of moderate to severe acute pain, acetaminophen and/or an NSAID may be as effective as an opioid. Immediate-release formulations of full opioid agonists should generally be used for acute pain that is severe enough to require treatment with an opioid. Use of extended-release or long-acting opioid formulations initially and treatment durations >1 week have been associated with an increased risk of unintended long-term use.
Abuse-Deterrent Opioids
The Medical Letter on Drugs and Therapeutics • June 5, 2017; (Issue 1522)
Development of abuse-deterrent opioid products,
including reformulation of existing products, has
become a priority for drug manufacturers and
public health advocates. Since our last article on
this...
Development of abuse-deterrent opioid products,
including reformulation of existing products, has
become a priority for drug manufacturers and
public health advocates. Since our last article on
this subject, several new abuse-deterrent opioid
formulations have been approved by the FDA,
including an oxycodone tablet formulation (Roxybond
– Inspirion) that is the first immediate-release opioid
product FDA-approved to include claims of abuse
deterrence in its labeling. No opioid formulation
prevents consumption of a large number of intact
dosage units, the most common method of abuse.
Abuse-deterrent formulations have one or more
properties that make their intentional nontherapeutic
use more difficult, less attractive, or less rewarding.
Arymo ER - A New Abuse-Deterrent Morphine Formulation
The Medical Letter on Drugs and Therapeutics • April 24, 2017; (Issue 1519)
The FDA has approved Arymo ER (Egalet), a new
extended-release, abuse-deterrent tablet formulation
of morphine sulfate, for management of pain severe
enough to require daily, around-the-clock,...
The FDA has approved Arymo ER (Egalet), a new
extended-release, abuse-deterrent tablet formulation
of morphine sulfate, for management of pain severe
enough to require daily, around-the-clock, long-term
opioid treatment and for which alternative treatment
options are inadequate. Arymo ER can only be
marketed to deter abuse by injection because another
single-entity, extended-release morphine product,
MorphaBond, which has not been marketed to date,
has marketing exclusivity for deterrence of abuse by
the intranasal route through October 2018.
A New Abuse-Deterrent Opioid - Xtampza ER
The Medical Letter on Drugs and Therapeutics • June 20, 2016; (Issue 1497)
The FDA has approved Xtampza ER (Collegium),
a new extended-release, abuse-deterrent capsule
formulation of oxycodone, for management of pain
severe enough to require daily, around-the-clock,
long-term...
The FDA has approved Xtampza ER (Collegium),
a new extended-release, abuse-deterrent capsule
formulation of oxycodone, for management of pain
severe enough to require daily, around-the-clock,
long-term opioid treatment and for which alternative
treatment options are inadequate.
Abuse-Deterrent Opioid Formulations
The Medical Letter on Drugs and Therapeutics • August 31, 2015; (Issue 1476)
Development of abuse-deterrent opioid products,
including reformulation of existing products, has
become a priority for drug manufacturers and public
health advocates. Three available opioid...
Development of abuse-deterrent opioid products,
including reformulation of existing products, has
become a priority for drug manufacturers and public
health advocates. Three available opioid formulations,
OxyContin (Purdue), Embeda (Pfizer), and Hysingla ER
(Purdue), now include claims of abuse deterrence in
their package inserts.
Extended-Release Hydrocodone (Hysingla ER) for Pain
The Medical Letter on Drugs and Therapeutics • May 11, 2015; (Issue 1468)
The FDA has approved a second extended-release (ER)
formulation of the oral opioid agonist hydrocodone
(Hysingla ER – Purdue) for management of pain severe
enough to require continuous long-term therapy...
The FDA has approved a second extended-release (ER)
formulation of the oral opioid agonist hydrocodone
(Hysingla ER – Purdue) for management of pain severe
enough to require continuous long-term therapy and
for which alternative treatment options are inadequate.
Hysingla ER tablets have abuse-deterrent properties
to discourage their misuse.
Extended-Release Oxycodone and Acetaminophen (Xartemis XR)
The Medical Letter on Drugs and Therapeutics • July 21, 2014; (Issue 1447)
The FDA has approved a fixed-dose extended-release
formulation of oxycodone and acetaminophen
(Xartemis XR – Mallinckrodt) for oral treatment of
acute pain severe enough to require an opioid. Oxycodone
is...
The FDA has approved a fixed-dose extended-release
formulation of oxycodone and acetaminophen
(Xartemis XR – Mallinckrodt) for oral treatment of
acute pain severe enough to require an opioid. Oxycodone
is available in the US as a single entity in oral
immediate-release (Oxecta, and others) and extendedrelease
(OxyContin) formulations. Immediate-release
oxycodone is also available in combination with aspirin
(Percodan, and others), acetaminophen (Percocet,
and others), or ibuprofen (see Table 1).